A Phase 3 interventional study of IVIG in Neonatal Sepsis, sponsored by Hormozgan University of Medical Sciences. Completed at 1 site in Iran, Islamic Republic of. Open to participants aged 1 Day to 7 Days. Per ClinicalTrials.gov, last updated 2016-11-04.
Sponsored by Hormozgan University of Medical Sciences · Phase 3, Interventional, and Prevention
Majority of healthcare authorities believe that due to the methodological weakness and small number of patients in conducted therapeutic trials, the evidences are insufficient to support the efficacy of intravenous immunoglobulin (IVIG) in prevention of preterm neonatal sepsis. The objective of this research is to determine the effect of intravenous immunoglobulin in prevention of preterm neonatal sepsis.
192 studies on the registry are indexed under Neonatal Sepsis; 41 are open to participants now.
This study's enrollment of 92 is below the median of 181 across 102 interventional studies indexed under Neonatal Sepsis.
Browse Neonatal Sepsis studies →Hormozgan University of Medical Sciences is the lead sponsor of 23 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
Drug: IVIG
No intervention
IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
Mortality
Death from sepsis or its related complications
Time frame: 7 days
Total number of days of hospitalization
Duration of hospitalization
Time frame: 7 days
Intraventricular Hemorrhage
occurrence of Intraventricular Hemorrhage
Time frame: 7 days
Necrotizing enterocolitis
occurrence of Necrotizing enterocolitis
Time frame: 7 days
Bronchopulmonary dysplasia
occurrence of Bronchopulmonary dysplasia
Time frame: 7 days
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Immunoglobulins, Intravenous
Hormozgan University of Medical Sciences